Marker Therapeutics, Inc.
MRKR · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $15 | $21 | $14 | $28 |
| - Cash | $18 | $10 | $14 | $19 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$3 | $11 | -$0 | $9 |
| Revenue | $1 | $1 | $0 | $2 |
| % Growth | 43.2% | 146.7% | -84.5% | – |
| Gross Profit | $1 | -$3 | -$3 | -$3 |
| % Margin | 100% | -385% | -798.1% | -125.9% |
| EBITDA | -$2 | -$4 | $0 | -$4 |
| % Margin | -162.1% | -494.8% | 0% | -171.5% |
| Net Income | -$2 | -$4 | -$4 | -$4 |
| % Margin | -162.1% | -466.3% | -1,273.6% | -170.4% |
| EPS Diluted | -0.12 | -0.29 | -0.4 | -0.42 |
| % Growth | 58.6% | 27.5% | 4.8% | – |
| Operating Cash Flow | -$3 | -$2 | -$5 | -$5 |
| Capital Expenditures | -$0 | $0 | -$0 | $0 |
| Free Cash Flow | -$3 | -$2 | -$5 | -$5 |